CSE$OSSUY

Embla Medical hf · Q2 2026 earnings

Q2 2026 earnings ·

Briefing

Embla Medical hf reported Q2 2026 revenue of USD 259 million, up 11% year-over-year with 6% organic growth.

Embla Medical hf delivered solid Q2 2026 results with net sales of USD 259 million, driven by strong 12% organic growth in Prosthetics & Neuro Orthotics. EBITDA margin expanded to 22%, net profit rose 39% to USD 29 million, and free cash flow reached USD 31 million. The company narrowed full-year organic growth guidance to 5-7% while reiterating EBITDA margin guidance of 20-22%.

  • Q2 revenue USD 259m (+11% reported, +6% organic); Prosthetics & Neuro Orthotics +12% organic.
  • EBITDA USD 58m (22% margin, +1pp YoY); net profit USD 29m (+39% YoY).
  • Free cash flow USD 31m (12% of sales); NIBD/EBITDA 2.2x within target range.
  • FY 2026 organic growth guidance narrowed to 5-7%; EBITDA margin guidance unchanged at 20-22%.

Headline financials

Total Revenue

$259M

No prior period
EPS (adj)

$0.07

No prior period
EBITDA

$58M

No prior period
Gross profit margin

63.0%

No prior period
Free Cash Flow

$31M

No prior period
Net Income

$29M

No prior period
Operating Income

$42M

No prior period
Gross Profit

$164M

No prior period
Total Assets

$1.72B

No prior period

Revenue by segment

Embla Medical hf · $269M total across 3 segments · Q2 2026

  • Prosthetics & Neuro Orthotics
    $151M—
  • Patient Care
    $79M—
  • Bracing & Supports
    $39M—

Forward guidance

Narrowed full-year 2026 organic sales growth guidance to 5-7% (previously 5-8%); EBITDA margin before special items guidance unchanged at 20-22%.

Tailwinds

  • Strong H1 performance and expected stronger H2 growth support narrowed guidance.
  • Continued cost discipline and Prosthetics momentum.

Headwinds

  • Patient Care segment still facing timing and market challenges in Europe.
  • US tariff environment remains uncertain.

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro